Document is current
Any future updates will be listed below
-
Authors
Haas, Meryl https://orcid.org/0000-0003-1958-2752
Hoeksma, Tino https://orcid.org/0009-0004-2953-5516
Mills, Jake T. https://orcid.org/0000-0002-4443-8296
Kelley, Cynthia https://orcid.org/0009-0009-6636-6834
Das, Arnab https://orcid.org/0009-0000-9916-9989
Shyam, Kankipati Teja https://orcid.org/0009-0007-5817-4483
Veenstra, Robin
Byford, Owen https://orcid.org/0009-0005-1152-5763
Hóf, Henrietta
Niemel, Coco
Donselaar, Tim
Drulyte, Ieva
van Kuppeveld, Frank J. M. https://orcid.org/0000-0001-5800-749X
Dulin, David https://orcid.org/0000-0003-4209-0377
Snijder, Joost https://orcid.org/0000-0002-9310-8226
Herod, Morgan R. https://orcid.org/0000-0002-8626-6787
Hurdiss, Daniel L. https://orcid.org/0000-0003-3834-5808
- License Information
-
More Information
Article History
Received: 22 August 2025
Accepted: 4 September 2026
First Online: 21 September 2026
Ethics
Competing interests: D.L.H. is a scientific co-founder of VirXcel B.V., a company developing antiviral therapies unrelated to the present study and may hold company shares. I.D. is a former employee of Thermo Fisher Scientific. The remaining authors declare no competing interests.
